Mechanisms for Laser-Induced Rejuvenation
ConditionSkin Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWright State University
About this trial
It has shown that laser wounding of geriatric skin protects it against skin cancer. The purpose of this study is to determine the origin of cells called fibroblasts which are present after treatment with Fractionated Laser Resurfacing (FLR). These cells restore a youth-like ultraviolet B (UVB) response, but where they come from is currently unknown. The study recruits subjects who are scheduled to undergo abdominoplasties to investigate the origin of those cells stimulated by laser treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult males and females 18 and older
Able to comprehend procedures and risks
Planning to undergo abdominoplasty surgery
Minimum amount of skin to be removed is 50 x 20cm
Disqualifiers
Medical history of not well-controlled diabetes. This is defined as a subject who needs high doses of insulin, recent history of hospitalization for diabetes-related complications, or poor wound health as evidenced by diabetic ulcers. Subjects who have been deemed healthy enough for abdominoplasty surgery would tend to suggest that their diabetes should not be an issue. However, if the subjects have diabetic complications as outlined above, they could affect the wound healing which is the object of this protocol so they would be excluded.
Pregnant or nursing
History of pathologically abnormal wound healing such as keloidal scars
Existing tattoos on the abdomen that are so extensive that they could interfere with the study
Trial design
Design model
Single group
Treatments tested in this trial
Fractionated Laser Resurfacing
DeviceA rejuvenating laser that makes tiny holes in the very superficial part of the skin.
Treatment groups
12 Participants
are divided into 1 treatment groupGroup A: Fractionated Laser ResurfacingExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
To test if the new fibroblasts that develop in response to fractionated laser resurfacing (FLR) wounding are derived from blood-derived monocytes.
Identify cells in the skin that have been wounded by FLR at 2 weeks and 1 week previously, for cells that co-express markers for both fibroblasts and monocytes by using single cell RNA-sequencing
Time frame
2 weeks prior to skin removal and 1 week prior to skin removal2
To test if possible cells transitioning from monocytes to fibroblasts are found in the top part of the dermis (papillary dermis).
Using tissue RNA-seq, PI will define if co-expressing cells are in the papillary dermis.
Time frame
2 weeks prior to skin removal and 1 week prior to skin removalSecondary outcomes
1
To define the number and types of cells populating the skin following fractionated laser resurfacing (FLR) wounding
Define the number and types of cells following FLR wounding at 2 weeks and 1 week prior to skin removal by using single-cell RNA-seq.
Time frame
2 weeks prior to skin removal and 1 week prior to skin removal2
To define the locations of the number of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Define the locations of the number cell following FLR wounding at 2 weeks and 1 week prior to skin removal by using tissue RNA-seq.
Time frame
2 weeks prior to skin removal and 1 week prior to skin removal3
To define the locations of the types of cells populating in the skin following fractionated laser resurfacing (FLR) wounding
Define the locations of the different cell types following FLR wounding at 2 weeks and 1 week prior to skin removal by using tissue RNA-seq.
Time frame
2 weeks prior to skin removal and 1 week prior to skin removalSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov